Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

He is just the fifth person in the world to be part of the clinical trial ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

A cancer diagnosis can be one of the most frightening moments in a person’s life. One of the first questions many people ask is how long they will live. This is a very natural question, but the answer ...

State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...

Delays in treating a patient with an aggressive form of prostate cancer more than likely contributed to his disease advancing ...

This may not apply in your husband’s case, but it’s worth having the conversation. The two meds Goldstein prescribes for men are flibanserin (Addyi), an oral tablet taken d ...

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...

Bellmunt Risk Score predicts survival in mCRPC across treatment lines. Learn how this simple tool can guide prognosis and treatment decisions. Read more.

Better continence, erectile function, but data on oncologic outcomes still 2 years away ...